Fibroblast growth factor receptor complexed with beta-Klotho co-receptor (FGFR–β-Klotho complex)

The fibroblast growth factor receptor complexed with beta-Klotho co-receptor is a heteromeric cell-surface signaling unit essential for mediating the actions of endocrine fibroblast growth factors—primarily FGF19 and FGF21. The canonical structure consists of an FGFR isoform bound together with β-Klotho; both components are required for high-affinity binding and signal transduction by these hormones. In this system: “Klotho proteins function as primary high-affinity receptors while FGFRs function as catalytic subunits that mediate intracellular signaling” [1][2][3]. Beta-klotho acts like a “zip code”-like determinant conferring tissue specificity on hormone action by restricting where these signals can be received—mainly liver, adipose tissue, pancreas, and some brain regions [4][5]. Upon ligand binding—such as by therapeutic mimetics—the activated complex triggers intracellular tyrosine kinase activity leading to broad metabolic effects including regulation of bile acid synthesis (via FGF19), glucose uptake/sensitivity (via both ligands), lipid metabolism (via both ligands), energy expenditure (notably via FGF21), among others. This pathway has become a major focus for drug development aimed at treating metabolic diseases such as type 2 diabetes mellitus and non-alcoholic fatty liver disease due to its central role in systemic energy balance [4][5].

Other names

FGFR–KLB complexFibroblast growth factor receptor–beta-Klotho complexFGF19/FGF21 receptor complexEndocrine FGF receptor complex

Drugs act primarily as agonists at the FGFR–β-Klotho complex to activate downstream metabolic pathways—most notably by mimicking endogenous endocrine fibroblast growth factors such as FGF19 or FGF21. This leads to modulation of glucose homeostasis, lipid metabolism, energy expenditure, and insulin sensitivity.